These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10580737)

  • 1. Pharmacokinetic and pharmacodynamic surrogate markers: studies with fluoroquinolones in patients.
    Schentag JJ
    Am J Health Syst Pharm; 1999 Nov; 56(22 Suppl 3):S21-4. PubMed ID: 10580737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.
    Hyatt JM; McKinnon PS; Zimmer GS; Schentag JJ
    Clin Pharmacokinet; 1995 Feb; 28(2):143-60. PubMed ID: 7736689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters.
    Pickerill KE; Paladino JA; Schentag JJ
    Pharmacotherapy; 2000 Apr; 20(4):417-28. PubMed ID: 10772373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoroquinolone benchmarking in relation to pharmacokinetic and pharmacodynamic parameters.
    Paladino JA; Callen WA
    J Antimicrob Chemother; 2003 May; 51 Suppl 1():43-7. PubMed ID: 12702703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using pharmacodynamic and pharmacokinetic surrogate markers in clinical practice: optimizing antimicrobial therapy in respiratory-tract infections.
    Nicolau DP
    Am J Health Syst Pharm; 1999 Nov; 56(22 Suppl 3):S16-20. PubMed ID: 10580736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models.
    Schentag JJ; Meagher AK; Forrest A
    Ann Pharmacother; 2003 Sep; 37(9):1287-98. PubMed ID: 12921513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic analysis of fluoroquinolones against Bacillus anthracis.
    Kihira T; Sato J; Shibata T
    J Infect Chemother; 2004 Apr; 10(2):97-100. PubMed ID: 15160302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine.
    McKellar QA; Sanchez Bruni SF; Jones DG
    J Vet Pharmacol Ther; 2004 Dec; 27(6):503-14. PubMed ID: 15601444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of fluoroquinolones.
    Turnidge J
    Drugs; 1999; 58 Suppl 2():29-36. PubMed ID: 10553702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of fluoroquinolones.
    Lode H; Borner K; Koeppe P
    Clin Infect Dis; 1998 Jul; 27(1):33-9. PubMed ID: 9675446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.
    Slavik RS; Jewesson PJ
    Clin Pharmacokinet; 2003; 42(9):793-817. PubMed ID: 12882587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maximizing efficacy and reducing the emergence of resistance.
    Wise R
    J Antimicrob Chemother; 2003 May; 51 Suppl 1():37-42. PubMed ID: 12702702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models.
    Schentag JJ
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S40-4. PubMed ID: 10984327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoroquinolone resistance in anaerobic bacteria following exposure to levofloxacin, trovafloxacin, and sparfloxacin in an in vitro pharmacodynamic model.
    Ross GH; Wright DH; Hovde LB; Peterson ML; Rotschafer JC
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2136-40. PubMed ID: 11408238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, microbiology, cost: interrelated problems for the 1990s that impact on the use of fluoroquinolone antimicrobial agents.
    Neu HC
    Am J Med; 1992 Apr; 92(4A):2S-7S. PubMed ID: 1580269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials.
    Li RC; Zhu M; Schentag JJ
    Clin Pharmacokinet; 1999 Jul; 37(1):1-16. PubMed ID: 10451780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in pharmacodynamic studies of antimicrobial resistance.
    Rapp RP; Campion JJ
    Ann Pharmacother; 2003 Sep; 37(9):1329-30. PubMed ID: 12921518
    [No Abstract]   [Full Text] [Related]  

  • 18. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia.
    Drusano GL; Preston SL; Fowler C; Corrado M; Weisinger B; Kahn J
    J Infect Dis; 2004 May; 189(9):1590-7. PubMed ID: 15116294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacodynamic and pharmacokinetic approaches to optimization of lomefloxacin].
    Iakovlev SV
    Antibiot Khimioter; 1998; 43(10):42-5. PubMed ID: 9825110
    [No Abstract]   [Full Text] [Related]  

  • 20. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
    Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
    J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.